Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results

Business Wire February 4, 2019

Q4 Earnings Preview For Gilead Sciences

Benzinga.com  February 4, 2019

8 Stocks To Watch For February 4, 2019

Benzinga.com  February 4, 2019

Earnings Scheduled For February 4, 2019

Benzinga.com  February 4, 2019

The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Benzinga.com  February 3, 2019

Analysts Cut AbbVie Price Targets After Earnings Miss

Benzinga.com  January 28, 2019

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

PR Newswire January 24, 2019

Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019

Business Wire January 22, 2019

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)

Business Wire January 8, 2019

Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Business Wire January 6, 2019

26 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  January 3, 2019

Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7

Business Wire January 2, 2019

28 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  December 24, 2018

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

Business Wire December 20, 2018

Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

Business Wire December 19, 2018

New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James

Benzinga.com  December 11, 2018

New Research Coverage Highlights Skyworks Solutions, Virtus Investment Partners, Altria Group, Gilead Sciences, Arthur J. Gallagher, and BP p.l.c — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire December 10, 2018

Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer

Business Wire December 10, 2018

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Business Wire December 4, 2018

China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6

Business Wire December 4, 2018